DK1237552T3 - Kombination af lumilysergol og riluzol for forebyggelse og/eller behandling af motorisk neuron-sygdomme - Google Patents

Kombination af lumilysergol og riluzol for forebyggelse og/eller behandling af motorisk neuron-sygdomme

Info

Publication number
DK1237552T3
DK1237552T3 DK00981467T DK00981467T DK1237552T3 DK 1237552 T3 DK1237552 T3 DK 1237552T3 DK 00981467 T DK00981467 T DK 00981467T DK 00981467 T DK00981467 T DK 00981467T DK 1237552 T3 DK1237552 T3 DK 1237552T3
Authority
DK
Denmark
Prior art keywords
riluzole
prevention
treatment
motor neuron
lumilyserol
Prior art date
Application number
DK00981467T
Other languages
English (en)
Inventor
Michel Dib
Jean-Marie Stutzmann
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1237552T3 publication Critical patent/DK1237552T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK00981467T 1999-12-01 2000-11-28 Kombination af lumilysergol og riluzol for forebyggelse og/eller behandling af motorisk neuron-sygdomme DK1237552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915139A FR2801793B1 (fr) 1999-12-01 1999-12-01 Association d'une ergoline et de riluzole et son utilisation comme medicament
PCT/FR2000/003314 WO2001039776A1 (fr) 1999-12-01 2000-11-28 Association d'une ergoline et du riluzole pour la prevention et le traitement des maladies motoneuronales

Publications (1)

Publication Number Publication Date
DK1237552T3 true DK1237552T3 (da) 2005-12-19

Family

ID=9552768

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00981467T DK1237552T3 (da) 1999-12-01 2000-11-28 Kombination af lumilysergol og riluzol for forebyggelse og/eller behandling af motorisk neuron-sygdomme

Country Status (10)

Country Link
EP (2) EP1464332A1 (da)
JP (1) JP5170926B2 (da)
AT (1) ATE302007T1 (da)
AU (1) AU1870501A (da)
DE (1) DE60022084T2 (da)
DK (1) DK1237552T3 (da)
ES (1) ES2245651T3 (da)
FR (1) FR2801793B1 (da)
MX (1) MXPA02005482A (da)
WO (1) WO2001039776A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100967258B1 (ko) 2005-05-10 2010-07-02 쉬드-케미아크티엔게젤샤프트 마이코톡신 흡착용 스테벤사이트의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173489B (it) * 1984-03-27 1987-06-24 Inverni Della Beffa Spa Procedimento di preparazione di 1-metil-10alfa-metossilumilisergolo e di suci esteri,e intermedi per la loro preparazione
IT1252163B (it) * 1991-12-03 1995-06-05 Poli Ind Chimica Spa Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
US6060483A (en) * 1996-06-27 2000-05-09 Pharmacia & Upjohn S.P.A. Antineurodegenerative ergoline derivatives
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
CA2317811A1 (en) * 1998-01-09 1999-07-15 Mor-Research Applications Ltd. Treatment of dyskinesias
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite

Also Published As

Publication number Publication date
JP5170926B2 (ja) 2013-03-27
FR2801793B1 (fr) 2003-07-04
EP1237552B1 (fr) 2005-08-17
MXPA02005482A (es) 2002-11-29
ATE302007T1 (de) 2005-09-15
DE60022084D1 (de) 2005-09-22
EP1464332A1 (fr) 2004-10-06
ES2245651T3 (es) 2006-01-16
JP2003515561A (ja) 2003-05-07
EP1237552A1 (fr) 2002-09-11
DE60022084T2 (de) 2006-06-01
WO2001039776A1 (fr) 2001-06-07
AU1870501A (en) 2001-06-12
FR2801793A1 (fr) 2001-06-08

Similar Documents

Publication Publication Date Title
ATE297204T1 (de) Heilmittel für neurodegenerative krankheiten
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
KR920019342A (ko) 골질환 치료제
NO982294L (no) Farmas°ytiske blandinger omfattende flurbiprofen
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
DK0589893T3 (da) Anvendelse af et bakteriocin som antimikrobielt middel til fremstilling af et lægemiddel til behandl ing af maveforstyrrelser forbundet med helicobacter pylori
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
DK0585681T3 (da) Anvendelse af IL-4-receptoren til behandling, forebyggelse og diagnose af infektionssygdomme
BR0113590A (pt) 7-oxo-piridopirimidinas
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DK515489A (da) Dispergerbar laegemiddelformulering
BR0008292A (pt) Derivados de mevinolina
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK1237552T3 (da) Kombination af lumilysergol og riluzol for forebyggelse og/eller behandling af motorisk neuron-sygdomme
GB9126874D0 (en) Medicaments
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DK47988D0 (da) Substituerede 3-phenyl-7h-thiazolooe3,2-baaoe1,2,4aatriazin-7-oner, deres fremstilling og anvendelse som laegemiddel, samt ved fremstillingen anvendelige mellemprodukter